November 10th 2023
Jaleh Fallah, MD, discusses the FDA's evaluation of data from the phase 2 LITESPARK-004 trial, which supported the approval of belzutifan in von Hippel-Lindau–associated cancers.
November 9th 2023
Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.
Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.
November 2nd 2023
Melissa L. Johnson, MD, Terufumi Kato, MD, and Pasi A. Jänne, MD, PhD, present updates from the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.
October 31st 2023
Two novel antibody-drug conjugates, HS-20089 and SGN-B7H4V, targeting the highly expressed immune checkpoint ligand B7-H4 have demonstrated manageable safety profiles and shown anti-tumor activity in first-in-human dose-escalation portions of phase 1 trials and will move forward to the next portions of the studies.
October 25th 2023
Denise M. Wolf, PhD, discusses the methods used to conduct the I-SPY2 study and the implications that immune biomarkers could have on selecting treatment for patients with hormone receptor–positive, HER2-negative breast cancer in the future.
October 24th 2023
Tian Zhang, MD, MHS, details how updated data presented at the 2023 ASCO Annual Meeting from trials such as KEYNOTE-426 and CLEAR have showed the sustained efficacy of VEGF plus immunotherapy combinations vs sunitinib in the first-line setting; discusses where the immunotherapy-only combination of ipilimumab and nivolumab fits in the frontline setting; and highlights how data from CONTACT-03 provided key insights on the use of immunotherapy in patients with advanced renal cell carcinoma after progression on a prior immune checkpoint inhibitor.
October 23rd 2023
The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.
October 21st 2023
Combination treatment with etigilimab and nivolumab was well tolerated in patients with recurrent or advanced solid tumors and promising efficacy was seen for patients with PD-L1 low disease
October 20th 2023
The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
October 18th 2023
The emergence of a novel class of compounds, known as anitens, potentially offers clinicians the ability to elongate responses for patients with metastatic castration-resistant prostate cancer, with the first-in-class N-terminal domain androgen receptor inhibitor masofaniten showing promise as it moves to the phase 2 portion of a phase 1/2 trial.
Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.
October 13th 2023
The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.
October 10th 2023
Combination therapy targeting multiple exons where mutations commonly develop in gastrointestinal stromal tumor may represent a promising treatment approach to increase efficacy when patients develop resistance to therapies such as imatinib.
September 30th 2023
The addition of venetoclax to carfilzomib and dexamethasone increased response rates compared with carfilzomib plus dexamethasone alone in patients with t(11:14)-positive relapsed/refractory multiple myeloma.
September 14th 2023
J. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
September 10th 2023
Adagrasib monotherapy provided durable efficacy for patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer, according to 2-year follow-up data from the phase 1/2 KRYSTAL-1 trial.
September 6th 2023
A predictive system developed using data from United States and European stem cell transplant registries was prognostic of survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.
September 5th 2023
The benzodiazepines lorazepam and alprazolam had differing effects on progression-free survival (PFS) outcomes among patients with pancreatic cancer, with lorazepam demonstrating an association with decreased PFS and alprazolam prolonging PFS.
Martin Wermke, MD, discusses why the novel agent may serve as a promising treatment option targeting DLL3.